FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 11 2025
0mins
Source: SeekingAlpha
Management Priorities: FibroGen's CEO highlighted key focuses including the sale of FibroGen China for approximately $210 million, advancing clinical trials for FG-3246 and FG-3180 in prostate cancer, and preparing for a pivotal Phase III trial for roxadustat in myelodysplastic syndromes, with an optimistic outlook on revenue and cash flow.
Financial Performance: The company reported a significant reduction in operating costs and expenses year-over-year, with total revenues expected to be between $6 million and $8 million for 2025, while maintaining a positive cash flow in Q2 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
